Open AccessSGLT-2 inhibitors in nephrotic-range proteinuria: emerging clinical evidence
Author(s) -
Zeynepgül Kalay,
Ozgun Ekin Sahin,
Sidar Çöpür,
Senem Danacı,
Alberto Ortíz,
Kevin Yau,
David Z.I. Cherney,
Mehmet Kanbay
Publication year - 2022
Publication title -
clinical kidney journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.033
H-Index - 40
eISSN - 2048-8513
pISSN - 2048-8505
DOI - 10.1093/ckj/sfac189
Subject(s) - medicine , proteinuria , albuminuria , nephrotic syndrome , kidney disease , randomized controlled trial , glycemic , blood pressure , diabetes mellitus , urology , kidney , endocrinology
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are a class of novel oral anti-hyperglycemic agents which are increasingly used in clinical practice. SGLT-2 inhibitors improve glycemic control and cardiorenal outcomes, promote weight loss, and reduce blood pressure. Randomized controlled trials have demonstrated that SGLT-2 inhibitors reduce proteinuria and delay progression of kidney disease in patients with albuminuria. However, whether SGLT-2 inhibitors have similar benefits in patients with nephrotic-range proteinuria has not been well established. Evidence to date has been limited to case reports, case series and secondary analyses of randomized controlled trials. This is the first comprehensive review on the effectiveness of SGLT-2 inhibitors for the treatment of patients with nephrotic-range albuminuria or proteinuria. Overall findings support a likely beneficial role of SGLT-2 inhibitors in reducing proteinuria and delaying chronic kidney disease progression in patients with nephrotic-range proteinuria.